.2 systems of poultry-keeping, including the use of living virulent agents to immunize against common respiratory infections. These created conditions ideal for intricate interactions between M. gallisepticum and other infections, notably infectious bronchitis virus (IBV) and certain serotypes of Escherichia coli, with Fahey-Crawley virus and Hwmophilus gallinarum of lesser significance. The incidence and severity of disease varies with the agent involved and the interval elapsing between exposure to M. gallisepticum and secondary infection. With IBV, immunity of the lower respiratory tract to M. gallisepticum is apparently overcome, and the organism spreads throughout, producing a chronic generalized infection. The most severe disease occurs when infection with IBV follows exposure to M. gallisepticum by one to three weeks. With E. coli, in addition to extensive respiratory disease, pericarditis and perihepatitis occur, due not to M. gallisepticum but to the coliform, which normally has only limited ability to produce disease. The period of greatest susceptibility to E. coli lies between one and a half and four weeks after M. gallisepticum infection. No special medium was employed as there was no reason to suspect mycoplasma infection when the specimens were received. Growth occurred on the anaerobic blood agar cultures which were reincubated from three to five days since no satisfactory growth was seen earlier to account for the patients' infections. These mycoplasmas are not anaerobes but need moisture for growth. Five of the 7 cases were serologically positive, the other 2 were not tested.
Four of these cases have been reported in detail with methods of isolation and serological tests (Stokes 1955 Eaton's agent was first recognized twenty years ago in association with certain cases of human lower respiratory tract infection. Some of these cases were known to develop cold agglutinins or antibody to Streptococcus M.G. in their serum during the course of the illness, but cultivation of Eaton's agent was difficult and most diagnostic laboratories found specific tests impracticable.
Growth of the organism on a solid cell-free medium was reported in 1962 (Chanock, Hayflick & Barile 1962) and subsequently it was shown that broth cultures of the organism were a satisfactory source of specific complement-fixing antigen (Chanock, James et al. 1962 ). Production of a similar antigen for diagnostic use in this country was begun. The human sera used for evaluation of the antigen were chosen so that results of the tests would give some indication of the prevalence of infection in cases admitted to hospital. These results are the subject of this report.
Preparation of Complement-fixing Antigen A strain of Mycoplasma pneumoniw was kindly provided by Professor B P Marmion, then at the Public Health Laboratory, Leeds. It was grown first on agar in Petri dishes and then after several subcultures was adapted to growth in broth. The
